FaR-RMS

FaR-RMS: An Overarching Study for Children and Adults with Frontline and Relapsed RhabdoMyoSarcoma

Agents: Several drug regimes, including Irinotecan, Actinomycin D, Doxorubicin, Ifosfamide, Vincristine, Vinorelbine, Cyclophosphamide, Temozolomide, radiotherapy, Regorafenib
Phase III
Status Recruiting
Sponsor University of Birmingham

 

For further information please also consult https://www.clinicaltrials.gov/study/NCT06797999

FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS).

 

WHO is the trial for?
  • Children and adults. No upper age limit
  • Histologically confirmed RMS diagnosis (except pleomorphic RMS)
  • Written informed consent from the patient and/or parents/guardians

Further criteria depending on the study phase.

WHAT is the key question that this trial is attempting to answer?

 FaR-RMS is an ongoing research programme with new lines of treatment being introduced depending on new data and innovations.

 

The study evaluates:

  • the impact of new agent regimens in both newly diagnosed and relapsed RMS.
  • how the duration of maintenance therapy affects the outcome.
  • whether changes to dose, extent (in metastatic disease) and timing of radiotherapy improve outcome and quality of life.
  • risk stratification through the use of PAX-FOXO1 fusion gene status instead of histological subtyping
  • the use of FDG PET-CT response assessment as a prognostic biomarker for outcome following induction chemotherapy.

WHY patients might want to participate?

 This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in sarcomas and potentially help other patients with this disease.

The trial might or might not have benefit in your individual case.

WHEN will the trial be open?

 This study is open for recruitment.

WHERE is the trial available?

 The trial is currently being conducted in Australia, Austria, Belgium, Czechia, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom. For further information check here.

 

Contact:

University of Birmingham, CRCTU Trial Management Team,

Email: farrms@trials.bham.ac.uk

 

Far-RMS - University of Birmingham

STUDY DESIGN: What does the study look like?

 FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS). It is a multi-arm, multi-stage format with several different test questions.

 

Newly diagnosed patients should, where possible, be entered into the FaR-RMS study at the time of first diagnosis prior to receiving any chemotherapy.

However, patients can enter at the point of radiotherapy or maintenance, and those with relapsed disease can enter the study even if not previously entered at initial diagnosis. Patients may be entered into more than one randomisation/registration, dependant on patient risk group and disease status.

HOW do I get more information?

 Patient organisations supporting sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving sarcoma patients.

 

If there are no such organisation in your country, please email us for more information: info@sarcoma-patients.eu

 

Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken